Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with rare cancers: targeted drug alectinib under trial

NCT ID NCT04774718

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 37 times

Summary

This study tests alectinib, a targeted cancer drug, in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to other treatments or have no standard therapy. About 42 participants will take alectinib capsules twice daily in 28-day cycles. Researchers will monitor safety, drug levels, and tumor response to see if the drug can control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK FUSION-POSITIVE SOLID OR CNS TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Beijing Children's Hospital, Capital Medical University

    RECRUITING

    Beijing, 100045, China

  • CHU Sainte-Justine

    RECRUITING

    Montreal, Quebec, H3T 1C5, Canada

  • Centre Léon Bérard, Institut d?Hémato-Oncologie Pédiatrique

    RECRUITING

    Lyon, 69373, France

  • Children's Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55404, United States

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • Dipartimento di Scienze Pediatriche Adolescenza

    RECRUITING

    Turin, Piedmont, 10126, Italy

  • Graacc-Grupo de Apoio ao adolescente e a crianca com cancer

    RECRUITING

    São Paulo, São Paulo, 04038-030, Brazil

  • Great North Children's Hospital

    RECRUITING

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Great Ormond Street Hospital

    RECRUITING

    London, WC1N 3JH, United Kingdom

  • Hospital Infantil Universitario Nino Jesus

    RECRUITING

    Madrid, 28009, Spain

  • Hospital Universitari i Politecnic La Fe

    RECRUITING

    Valencia, 46026, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41 41013, Spain

  • Hospital de Cancer de Barretos

    RECRUITING

    Barretos, São Paulo, 14784-400, Brazil

  • Hôpital de la Timone, Oncologie Pédiatrique

    RECRUITING

    Marseille, 13385, France

  • Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris

    RECRUITING

    Paris, 75248, France

  • Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS

    ACTIVE_NOT_RECRUITING

    Genoa, Liguria, 16147, Italy

  • Istituto Nazionale Tumori di Milano

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • Johns Hopkins All Children's Hospital

    RECRUITING

    St. Petersburg, Florida, 33701, United States

  • Lucile Packard Children's Hospital

    RECRUITING

    Palo Alto, California, 94304, United States

  • Memorial Sloan Kettering Cancer Center

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

  • Rigshospitalet

    RECRUITING

    København Ø, 2100, Denmark

  • Royal Children's Hospital

    RECRUITING

    Parkville, Victoria, 3052, Australia

  • Royal Manchester Childrens Hospital

    RECRUITING

    Manchester, M13 9WL, United Kingdom

  • Royal Marsden Hospital (Sutton)

    WITHDRAWN

    Sutton, SM2 5PT, United Kingdom

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • St. Jude Children'S Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

  • Sydney Children's Hospital

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • The Hospital for Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • University of Michigan, C.S. Mott Children's Hospital

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Universitätsklinikum Heidelberg

    WITHDRAWN

    Heidelberg, 69120, Germany

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, 200092, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

alectinib (a targeted cancer drug taken as capsules twice daily)

What this could lead to

If it works, this could offer a new treatment option for children with these rare, hard-to-treat tumors.

What could go wrong

This is an early-phase trial with only 42 participants, so results may not apply to all patients. Side effects are possible, and the drug may not shrink tumors in everyone.

Conditions

The condition(s) this trial relates to.

central nervous system cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK FUSION-POSITIVE SOLID OR CNS TUMORS